{
    "organizations": [],
    "uuid": "69e987aff0314da63911062987be5d7c6d7f589d",
    "author": "",
    "url": "https://www.reuters.com/article/idUSL8N1P30UN",
    "ord_in_thread": 0,
    "title": "BRIEF-Sanofi And Alnylam Pharmaceuticals Enter Into Partnership",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 8, 2018 / 7:25 AM / Updated 2 hours ago BRIEF-Sanofi And Alnylam Pharmaceuticals Enter Into Partnership Reuters Staff \nJan 8 (Reuters) - SANOFI SA: \n* AND ALNYLAM, ANNOUNCED ON SUNDAY STRATEGIC RESTRUCTURING OF RNAI THERAPEUTICS RARE DISEASE ALLIANCE \n* SANOFI WILL OBTAIN GLOBAL DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO FITUSIRAN \n* GLOBAL COMMERCIALIZATION OF FITUSIRAN, UPON APPROVAL, WILL BE DONE BY SANOFI GENZYME \n* ALNYLAM WILL RECEIVE ROYALTIES BASED ON NET SALES OF FITUSIRAN PRODUCTS \n* ALNYLAM TO OBTAIN GLOBAL DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO ITS INVESTIGATIONAL RNAI THERAPEUTICS PROGRAMS FOR THE TREATMENT OF ATTR AMYLOIDOSIS, INCLUDING PATISIRAN AND ALN-TTRSC02 \n* SANOFI WILL RECEIVE ROYALTIES BASED ON NET SALES OF THESE ATTR AMYLOIDOSIS PRODUCTS \nSource text for Eikon:",
    "published": "2018-01-08T09:23:00.000+02:00",
    "crawled": "2018-01-08T09:34:20.062+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "updated",
        "hour",
        "ago",
        "alnylam",
        "pharmaceutical",
        "enter",
        "partnership",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "sanofi",
        "sa",
        "alnylam",
        "announced",
        "sunday",
        "strategic",
        "restructuring",
        "rnai",
        "therapeutic",
        "rare",
        "disease",
        "alliance",
        "sanofi",
        "obtain",
        "global",
        "development",
        "commercialization",
        "right",
        "fitusiran",
        "global",
        "commercialization",
        "fitusiran",
        "upon",
        "approval",
        "done",
        "sanofi",
        "genzyme",
        "alnylam",
        "receive",
        "royalty",
        "based",
        "net",
        "sale",
        "fitusiran",
        "product",
        "alnylam",
        "obtain",
        "global",
        "development",
        "commercialization",
        "right",
        "investigational",
        "rnai",
        "therapeutic",
        "program",
        "treatment",
        "attr",
        "amyloidosis",
        "including",
        "patisiran",
        "sanofi",
        "receive",
        "royalty",
        "based",
        "net",
        "sale",
        "attr",
        "amyloidosis",
        "product",
        "source",
        "text",
        "eikon"
    ]
}